These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3759278)

  • 1. Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone.
    Maleev A; Vlahov V; Gruev I; Dierdorf D; Kostova N; Bacracheva N
    Int J Clin Pharmacol Ther Toxicol; 1986 Aug; 24(8):425-9. PubMed ID: 3759278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
    Soma LR; Uboh CE; Rudy JA; Smith MS
    Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nabumetone (BRL 14777) presystemic elimination and disposition in patients with liver impairments.
    Terziivanov D; Maleev A; Vlahov V
    Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):208-13. PubMed ID: 2884189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.
    Kendall MJ; Chellingsworth MC; Jubb R; Thawley AR; Undre NA; Kill DC
    Eur J Clin Pharmacol; 1989; 36(3):299-305. PubMed ID: 2744071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by HPLC].
    Qin Y; Zou Y; Liang M; Huang Y; Yu Q
    Hua Xi Yi Ke Da Xue Xue Bao; 1999 Dec; 30(4):452-4. PubMed ID: 11387968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nabumetone--a novel anti-inflammatory drug: bioavailability after different dosage regimens.
    von Schrader HW; Buscher G; Dierdorf D; Mügge H; Wolf D
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):672-6. PubMed ID: 6526543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Giersch KH; Münzel P
    Drugs; 1990; 40 Suppl 5():57-61. PubMed ID: 2081495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
    Nobilis M; Mikušek J; Szotáková B; Jirásko R; Holčapek M; Chamseddin C; Jira T; Kučera R; Kuneš J; Pour M
    J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography.
    de Jager AD; Hundt HK; Hundt AF; Swart KJ; Knight M; Roberts J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):247-51. PubMed ID: 10821411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphonuclear leukocytes activation: in vitro modulation by 6-methoxy-2-naphthylacetic acid, the major active metabolite of nabumetone.
    Allegrezza-Giulietti A; Serretti R; Peroni M; Cervini C
    Pharmacol Res; 1993 Sep; 28(2):163-73. PubMed ID: 8278307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the clinical pharmacokinetics of nabumetone.
    Hyneck ML
    J Rheumatol Suppl; 1992 Nov; 36():20-4. PubMed ID: 1474531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection].
    Nespesná L; Stícha M; Matousková O; Perlík F; Slanar O
    Ceska Slov Farm; 2011 Feb; 60(1):17-24. PubMed ID: 21650014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses.
    von Schrader HW; Buscher G; Dierdorf D; Mügge H; Wolf D
    Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):311-21. PubMed ID: 6688407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of enterohepatic circulation of the active metabolite of nabumetone in humans.
    Brett MA; Buscher G; Ellrich E; Greb WH; Kurth HJ; Rülander G; Schmerenbeck B; Haddock R; Thawley A
    J Rheumatol Suppl; 1992 Nov; 36():81-2. PubMed ID: 1474541
    [No Abstract]   [Full Text] [Related]  

  • 15. Nabumetone. Evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans.
    Brett MA; Buscher G; Ellrich E; Greb WH; Kurth HJ; Rülander G; Schmerenbeck B; Haddock RE; Thawley AR
    Drugs; 1990; 40 Suppl 5():67-70. PubMed ID: 2081498
    [No Abstract]   [Full Text] [Related]  

  • 16. Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect.
    Světlík S; Štícha M; Matoušková O; Nespěšná L; Sklenář Z; Bartůněk A; Perlík F; Slanař O
    Am J Ther; 2016; 23(6):e1498-e1503. PubMed ID: 25393072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment.
    Boelaert JR; Jonnaert HA; Daneels RF; Schurgers ML; Thawley AR; Undre NA; Cooper DL
    Am J Med; 1987 Oct; 83(4B):107-9. PubMed ID: 3687998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
    Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
    Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [6-methoxy-2-naphthylacetic acid level in plasma, synovial fluid and adjacent tissue in patients with rheumatoid arthritis or gonarthroses after a 4-day therapy with nabumetone (Arthaxan)].
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Fedder M
    Z Rheumatol; 1991; 50(2):103-8. PubMed ID: 1872041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid
    Matsumoto K; Hasegawa T; Ohara K; Kamei T; Koyanagi J; Akimoto M
    Xenobiotica; 2021 Feb; 51(2):155-166. PubMed ID: 33146575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.